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Available online xxxxBackground: Despite the epidemic of cardiovascular disease and the benefits of cardiac rehabilitation (CR), avail-
ability is known to be insufficient, although this is not quantified. This study ascertained CR availability, volumes
and its drivers, and density.
Methods: A survey was administered to CR programs globally. Cardiac associations and local champions facili-
tated program identification. Factors associated with volumes were assessed using generalized linear mixed
models, and compared byWorldHealthOrganization region. Density (i.e. annual ischemic heart disease [IHD] in-
cidence estimate from Global Burden of Disease study divided by national CR capacity) was computed.
Findings: CRwas available in 111/203 (54.7%) countries; data were collected in 93 (83.8% country response; N=
1082 surveys, 32.1% program response rate). Availability by region ranged from 80.7% of countries in Europe, to
17.0% inAfrica (p b .001). Therewere 5753programs globally that could serve 1,655,083 patients/year, despite an
estimated 20,279,651 incident IHD cases globally/year. Volume was significantly greater where patients were
systematically referred (odds ratio [OR]= 1.36, 95% confidence interval [CI] = 1.35–1.38) and programs offered
alternative models (OR = 1.05, 95%CI = 1.04–1.06), and significantly lower with private (OR = .92, 95%CI =
.91–.93) or public (OR = .83, 95%CI = .82–84) funding compared to hybrid sources.
Median capacity (i.e., number of patients a program could serve annually) was 246/program (Q25-Q75 =
150–390). The absolute density was one CR spot per 11 IHD cases in countries with CR, and 12 globally.
Interpretation: CR is available in only half of countries globally.Where offered, capacity is grossly insufficient, such
that most patients will not derive the benefits associated with participation.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Global health
Health services1. Introduction
Cardiovascular diseases (CVDs) are among the leading burdens of
disease and disability globally [1,2]. In 2015, there were 422.7 million
CVD cases around theworld [2]. Secondary prevention is needed tomit-
igate the reduced quality and quantity of life in patients with this
chronic disease. Cardiac rehabilitation (CR) is a cost-effective model of
care shown to reduce cardiovascular mortality and morbidity by 20%
[3,4].
Despite guidelines promoting referral to CR [5], and the clear associ-
ation between availability and utilization [6], previous estimates sug-
gested it is not available in over 60% of countries worldwide, and
where it exists there is insufficient supply to meet growing need [7,8].
There has been one review of the literature globally [7], and another
in low and middle-income countries [9], which has characterized CR
availability, but to date there has been no primary study which has
ascertained in which countries CR exists. Moreover, there have been a
few studieswhich have characterized CR capacity at national or regional
levels but not at a global level [10–12], and nonehave juxtaposed supply
in relation to burden of diseases indicated for CR as per clinical practice
guideline recommendations (i.e., density).
Accordingly, the aimsof this studywere to establishCR: (1) availabil-
ity, (2a) volumes served and capacity, and (b) the factors associatedSupervia, F. Lopez-Jimenez, etwith greater volume. Given this was the first study to establish CR vol-
umes globally andnoprevious researchhas examined factors associated
with program volumes to our knowledge, tests of association were ex-
ploratory. The study also aimed to establish CR: (3) density and (4) bar-
riers to broader delivery. As applicable, these were described by
program, country (including consideration of CR-indicated disease bur-
den),World Health Organization (WHO) region, and globally. It was hy-
pothesized there would be significant regional variation as well as in
terms of disease burden in many of these parameters given the reviews
outlined above [7,9]; however again, these analyses were exploratory
given this is the first time CR has been scoped on a global scale.
2. Methods
2.1. Design & Procedure
This was a cross-sectional study. The study procedures were ap-
proved by York University's Office of Research Ethics (Toronto,
Canada) and Mayo Clinic's Institutional Review Board (Rochester,
United States). Participating CR centers provided informed consent
electronically.
First, a list of all countries globally was compiled, by cross-
referencing several key sources, including WHO [13,14]. Small islandsal., Cardiac Rehabilitation Availability and Density around the Globe, ,
Research in context
Evidence before this study
Cardiac rehabilitation (CR) is an effective secondary preven-
tion strategy for one of the leading burdens of disease and the
leading cause of death globally, namely cardiovascular disease.
Reviews of the literature, however, suggested CR was only
available in b40% of countries globally, and density, characterized
in only several countries, was highly variable. Therefore, it is un-
known how many patients can access these guideline-
recommended services around the world, and where the greatest
gaps exist.
Added value of this study
Cardiac rehabilitation availability around the world has been
established for the first time. Based on primary data collected
through this global survey, CR was shown to be available in
54·7% countries (median= 4 programs/country). The 5,753 pro-
grams in theworld served amedian of 157 (Q25–Q75= 75–350)
patients/year each. Programs that had systematic inpatient refer-
ral, hybrid funding sources and offered alternative models served
significantly more patients, among other factors. Median national
capacity in countries with CR was 1500 (Q25–75 = 300–7500)
patients/year (120 across all countries globally). Where available,
the densitywas oneCR spot per 11 incident annual ischemic heart
disease patients globally (lowest in Africa, greatest in Western
Pacific).
Implications of all the available evidence
CR availability, capacity, and density are vastly insufficient to
serve all patients in need.
Advocacy to develop greater capacity, particularly in Africa
and South-East Asia, is needed to ensure all guideline-indicated
patients derive the 20% mortality and re-hospitalization reduc-
tions associated with participation. Policies should promote
greater public funding and support programs in delivering pro-
gramming outside of clinical centers.
3K. Turk-Adawi et al. / EClinicalMedicine xxx (xxxx) xxxaffiliated with larger countries were considered part of the larger coun-
try (e.g., Macau), and United Kingdom countries were considered sepa-
rately given their disparate CR practices and policies. Two hundred and
three countries were considered (Tables 1 and 2). Some of these coun-
tries are not categorized by WHO. These countries were allocated to
the most applicable geographic region.
The incidence of CVD (i.e., practice guidelines for most of these dis-
eases recommend CR) in each country [5], to represent the number of
patients who would be indicated for CR in a given year (i.e., need),
was sought. Estimates from the Global Burden of Disease (GBD) study
were used [15], from 2016. Because the CVD grouping included rheu-
matic heart disease and stroke, to be conservative, ischemic heart dis-
ease (IHD) more specifically was selected, as it was the closest
diagnostic option to CR-indicated conditions [16]. We created IHD inci-
dence tertiles (Fig. 1). These datawere usedwith the data on availability
and capacity collected as per below to compute density.
With regard to availability, the following strategies and sourceswere
used to confirm which countries offered any CR: (a) our previously-
published review on global availability of CR [7], among other reviews
[9], and (b) a search of MEDLINE, EMBASE, and Google Scholar for arti-
cles or abstracts on CR. For countries where no CR was in evidence, the
authors: (a) searched the internet via Google using the term “cardiac re-
habilitation” and country, (b) searched via Google for hospitals withinPlease cite this article as: K. Turk-Adawi, M. Supervia, F. Lopez-Jimenez, et
https://doi.org/10.1016/j.eclinm.2019.06.007these countries, which were then searched for CR programs, (c) used a
snowball sampling strategy via the International Council of Cardiovas-
cular Prevention and Rehabilitation (ICCPR) members and key infor-
mants in the field (including European Society of Cardiology national
CVD prevention coordinators), as well as (d) attended international
conferences of relevant societies to approach experts in the given coun-
tries (the latter 2 enabled us to identify programs that may not be ad-
vertised in English). Finally, before any country was designated as
having no CR, international societies (e.g., International Society of Phys-
ical Medicine and Rehabilitation, African Heart Network) were
contacted to ascertain whether there were any CR programs in coun-
tries where we lacked confirmation of availability.
In countries where CR existed, the total number of programs and
contacts to reach those programs for data collection was then sought.
First, available CR associations (or broader cardiac society leadership
where not available) were contacted. Otherwise, “champions” were
identified from the peer-reviewed, or gray literature/internet. Identified
leaders were sent an e-mail requesting their collaboration. If there was
no “champion” for a given country, the study teamdirectly contacted CR
programs that could be identified on the internet or through key infor-
mants. Based on the above, the total number of CR programs in each
country was collated.
Finally, national champions were asked to circulate a link of the sur-
vey to all identified programs, or provide the study teamwith the email
addresses of the programs to survey them directly. Data collection oc-
curred from February 2016–July 2017 via online survey administered
through REDCap.
2.2. Sample
The sample was comprised of all CR programs world-wide offering
Phase II (i.e., post-acute care discharge) services (including residential
programs [17]. Programs that offered: (1) initial assessment, (2) struc-
tured exercise, and (3) at least one other strategy to control CV risk fac-
tors, were included. All CR programs were contacted in countries with
≤350 programs; otherwise, a random non-stratified subsamples of
250 programs were generated electronically (using the simple random
sample module SAS institute, Cary, NC) and were contacted.
2.3. Measures
This study focused on fourmain indicators, namely CR: (1) availabil-
ity or existence (yes/no; ascertained as described above); (2) program
volume, defined as the number of patients served by a program annu-
ally, (3) national capacity, or the median number of patients a program
could serve annually (as both reported through the survey described
below) among the responding programs in a given country, multiplied
by the total number of programs in that country (ascertained from
champion; Please note for countries where no surveys were completed,
national capacity was computed by multiplying the number of pro-
grams by regional median program capacity); and (4) density, or na-
tional capacity (#3 above) per annual incident IHD case in a country
(ascertained from GBD) [15]. The latter was ranked by country.
Development of the survey is described elsewhere [18]; it was pilot-
tested in the Arabworld and Canada. The final versionwas translated to
Portuguese, Spanish, and traditional Chinese character [19]. The survey
assessed annual program volume, capacity (both defined as per the
above), and barriers to serving more patients (e.g., referral, human re-
sources; rated on a 5-point Likert scale; and an open-ended item).
Because this was the first study to examine volume worldwide, po-
tential factors associated with volume were selected based on expert
opinion of the authors. Potential drivers of volume assessed included:
(i) funding source, and the costs per patient, (ii) location of program
and proximity to other programs; (iii) type and nature of institution
where situated, (iv) healthcare professionals on the CR team, (v) wait
times, (vi) number of patients served per session (as well as staff-to-al., Cardiac Rehabilitation Availability and Density around the Globe, ,
Table 1
Cardiac rehabilitation availability, volume, capacity, and density by country with any cardiac rehabilitation, N = 111.
WHO Region Human
Development
Index*
IHD incidence† Year 1st CR
program
# CR
programs
in
country
Median annual
volume/program
Median annual
capacity/program
National CR
capacity‡
CR density§
CR
density
ranking||
African (8 countries)
Algeria 0.745 140,592 NA 1 NA 55 55 2556 72
Benin 0.485 11,973 NA 1 NA 55 55 218 57
Kenya 0.555 55,174 2010 3 20 50 150 368 62
Mauritius 0.513 3872 2013 1 60 60 60 65 46
Nigeria 0.527 223,994 2012 1 50 50 50 4480 73
South Africa 0.666 108,455 1989 23 50 90 2070 52 41
Tanzania 0.531 64,326 NA 1 NA 55 55 1170 69
Uganda 0.493 31,951 NA 1 NA 55 55 581 65
Mean ± SD 0.564 ± 0.092 80,042 ± 74,459 2006 ± 11 4 ± 8 45 ± 15 59 ± 13 319 ± 708
1186
± 1569
61 ± 12
Median (Q25-Q75)
0.529
(0.498–0.638)
59,750
(16968–132,558)
2011
(1994–2013)
1 (1–3) 50 (28–58) 55 (51–59) 55 (55–128)
474
(103–2210)
64
(49–71)
Americas (28 countries)
Argentina 0.827 122,357 1998 23 1500 2000 46,000 3 5
Aruba NA NA NA 1 NA 200 200 NA NA
Barbados 0.795 1240 1994 1 70 96 96 13 18
Bermuda NA 197 2012 1 220 400 400 1 1
Brazil 0.754 529,062 1973 75 60 72 5400 98 51
Canada 0.920 91,030 1960 170 300 300 51,000 2 3
Chile 0.847 45,008 2009 10 30 200 2000 23 28
Colombia 0.727 75,245 1972 50 410 390 19,500 4 7
Costa Rica 0.776 8288 1985 6 45 120 720 12 17
Cuba 0.775 49,789 1973 8 145 180 1440 35 33
Curaçao NA NA NA 2 120 200 400 NA NA
Dominican Republic 0.722 193,919 2016 2 NA 200 400 485 64
Ecuador 0.739 27,046 1995 5 36 190 950 29 30
El Salvador 0.680 9129 NA 2 NA 200 400 23 28
Grenada 0.754 296 NA 1 NA 200 200 1 2
Guam NA 311 NA 1 NA 200 200 2 3
Guatemala 0.640 13,671 2011 2 18 60 120 114 52
Honduras 0.625 10,939 2005 2 20 20 40 274 58
Jamaica 0.730 8026 2006 3 24 60 180 45 39
Mexico 0.762 161,348 1944 24 38 250 6000 27 29
Panama 0.788 5039 2006 1 38 80 80 63 44
Paraguay 0.693 14,892 2011 3 125 200 600 25 29
Peru 0.740 49,967 1992 10 80 250 2500 20 25
Puerto Rico NA 15,286 NA 1 NA 200 200 76 47
Trinidad and Tobago 0.780 4759 NA 2 NA 200 400 12 17
United States of America 0.920 1,344,974 1970 2632 150 208 547,456 3 6
Uruguay 0.795 10,656 1970 12 120 200 2400 4 8
Venezuela 0.767 45,575 1974 9 103 163 1467 31 32
Mean ± SD 0.763 ± 0.072 78,241 ± 233,742 1989 ± 20
109
± 496
174 ± 320 251 ± 354
24,670
± 103,253
55 ± 104 26 ± 19
Median (Q25-Q75)
0.762
(0.727–0.795)
10,656
(1152–47,682)
1994
(1973–2008)
3 (1–12) 80 (37–148) 200 (131–206)
500
(200–2475)
23 (4–49)
28
(7–41)
Eastern Mediterranean (12 countries)
Afghanistan 0.479 89,056 2014 1 100 150 150 594 5766
Bahrain 0.824 3842 1998 1 140 500 500 8 12
Egypt 0.691 369,488 2010 2 20 100 200 1847 70
Iran 0.774 235,157 1994 34 250 475 16,150 15 20
Kuwait 0.800 7648 NA 1 NA 246 246 31 32
Lebanon 0.763 27,633 2014 1 100 300 300 92 49
Morocco 0.647 156,088 2016 1 NA 246 246 635 67
Pakistan 0.550 622,146 2004 4 900 1500 6000 104 63
Qatar 0.856 7003 2013 1 157 192 192 37 34
Saudi Arabia 0.847 82,510 NA 1 NA 246 246 335 60
Tunisia 0.725 50,217 2010 1 90 150 150 335 59
United Arab Emirates 0.840 21,885 NA 1 NA 246 246 89 48
Mean ± SD 0.733 ± 0.121 139,389 ± 187,985 2008 ± 8 4 ± 9 220 ± 283 363 ± 378 1677 ± 4573 369 ± 518 48 ± 20
Median (Q25-Q75)
0.763
(0.658–0.836)
66,363
(11,208–215,389)
2010
(2001–2014)
1 (1–2) 120 (93–227) 246 (161–431)
246
(194–450)
213
(32–549)
54
(33–65)
Europe (46 countries)
Austria 0.893 32,901 1962 26 750 200 5200 6 10
Belarus 0.796 88,874 1981 5 300 300 1500 59 44
Belgium 0.896 66,985 1977 48 275 300 14,400 5 9
Bosnia and Herzegovina 0.750 19,068 1959 1 800 2000 2000 10 15
Bulgaria 0.794 55,871 1958 1 2200 3000 3000 19 24
Croatia 0.827 26,066 1957 3 940 940 2820 9 14
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Table 1 (continued)
WHO Region Human
Development
Index*
IHD incidence† Year 1st CR
program
# CR
programs
in
country
Median annual
volume/program
Median annual
capacity/program
National CR
capacity‡
CR density§
CR
density
ranking||
Cyprus 0.856 2665 NA 1 NA NA NA NA 11
Czech Republic 0.878 66,012 1993 15 65 200 3000 22 27
Denmark 0.925 23,455 1990 35 200 250 8750 3 6
England 0.909 318,284 1978 266 490 500 133,000 2 4
Estonia 0.865 10,938 1994 2 150 150 300 37 35
Finland 0.89 25,677 1978 25 55 98 2450 11 16
France 0.897 259,251 1972 130 475 485 63,050 4 8
FYR of Republic of Northern
Macedonia
0.748S 8285 NA 1 NA 375 375 22 27
Georgia 0.769 16,488 1994 17 180 600 10,200 2 4
Germany 0.926 385,474 1950 120 800 825 99,000 4 8
Greece 0.866 61,036 1993 4 20 100 400 153 54
Hungary 0.836 69,698 1970 33 440 580 19,140 4 8
Iceland 0.921 1570 1983 4 168 185 740 2 4
Ireland 0.923 16,000 1985 37 256 300 11,100 1 6
Israel 0.899 23,152 1964 22 1000 1000 22,000 1 2
Italy 0.887 359,226 1974 221 350 355 78,455 5 9
Kazakhstan 0.794 57,125 NA 1 NA 375 375 152 53
Kyrgyz Republic 0.664 11,398 NA 1 NA 375 375 NA 31
Latvia 0.830 14,743 1997 2 150 400 800 18 23
Lithuania 0.848 23,421 1977 25 950 1000 25,000 1 2
Luxembourg 0.898 1683 NA 4 NA 375 1500 1 2
Malta 0.856 1958 2012 1 300 900 900 2 4
Moldova 0.699 21,376 2016 1 200 400 400 53 42
Montenegro 0.807 3049 NA 1 NA 375 375 8 13
Netherlands 0.924 88,550 1974 90 555 450 40,500 2 4
Northern Ireland NA 8811 1980 13 255 215 2795 3 6
Norway 0.949 15,197 NA 35 NA 375 13,125 41 37
Poland 0.855 237,460 1973 56 350 375 21,000 11 16
Portugal 0.843 35,884 1988 23 75 100 2300 16 21
Romania 0.802 126,835 1978 3 1400 2500 7500 17 22
Russia 0.804 1,223,642 2010 3 400 500 1500 816 68
Scotland NA 30,185 1985 69 356 296 20,424 1 2
Serbia 0.776 40,265 1968 2 1345 1570 3140 13 19
Slovak Republic 0.845 29,436 2015 7 50 200 1400 21 26
Slovenia 0.890 11,135 1995 2 100 150 300 37 35
Spain 0.884 175,537 1993 87 120 120 10,440 17 22
Sweden 0.913 50,475 NA 69 150 150 10,350 5 9
Switzerland 0.939 29,546 1997 51 255 255 13,005 2 4
Turkey 0.767 337,617 2010 10 100 350 3500 97 50
Wales NA 15,432 1986 17 490 375 6375 2 4
Mean ± SD 0.852 ± 0.065 98,429 ± 198,290 1984 ± 17 35 ± 55 466 ± 463 550 ± 604
14,536
± 27,142
38 ± 122 19 ± 17
Median (Q25-Q75)
0.861
(0.804–0.898)
29,491
(15,084-74,411)
1984
(1974–1994)
14 (2–40) 300 (150–750) 375 (211–520)
3070
(875–13,444)
9(2–22)
14
(6–27)
South-East Asia (6 countries)
Bangladesh 0.579 409,210 NA 1 160 200 200 2046 71
India 0.624 3,313,674 1997 23 200 400 9200 360 61
Indonesia 0.689 66,676 1985 13 98 100 1300 51 40
Nepal 0.558 66,134 2008 1 2000 3000 3000 22 27
Sri Lanka 0.766 66,927 2012 4 114 105 420 159 55
Thailand 0.740 199,828 NA 5 NA 200 1000 200 56
Mean ± SD 0.659 ± 0.086
687,075 ±
1,293,730
2001 ± 12 8 ± 9 514 ± 831 668 ± 1148 2520 ± 3419 473 ± 780 52 ± 16
Median (Q25-Q75)
0.656
(0.573–0.747)
133,378
(66541–1,135,326)
2003
(1998–2011)
5 (1–16) 160 (106–1100) 200 (104–1050)
1150
(365–4550)
179
(44–782)
56
(37–64)
Western Pacific (11 countries)
Australia 0.939 80,169 1970 314 200 200 62,800 1 2
Brunei 0.865 471 2004 2 55 80 160 3 6
China 0.738 3,104,203 1984 216 300 325 70,200 44 38
Japan 0.903 501,740 1990 325 150 300 97,500 5 9
Malaysia 0.789 86,224 2007 6 300 250 1500 58 43
Mongolia 0.735 5241 2013 1 NA 250 250 21 25
New Zealand 0.915 10,110 1968 43 200 146 6278 2 4
Philippines 0.682 217,107 1975 10 105 560 5600 39 36
Singapore 0.925 14,299 1979 7 260 438 3066 5 9
South Korea 0.901 94,661 2009 17 200 250 4250 22 27
Taiwan NA 43,795 1978 35 70 180 6300 7 11
Mean ± SD 0.839 ± 0.094 378,002 ± 873,254 1989 ± 16 89 ± 124 181 ± 80 271 ± 135
23,446
± 35,315
19 ± 20 19 ± 15
(continued on next page)
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Table 1 (continued)
WHO Region Human
Development
Index*
IHD incidence† Year 1st CR
program
# CR
programs
in
country
Median annual
volume/program
Median annual
capacity/program
National CR
capacity‡
CR density§
CR
density
ranking||
Median (Q25-Q75)
0.883
(0.737–0.918)
80,169
(10110–217,107)
1984
(1975–2007)
17
(6–216)
200 (96–263) 250 (180–250)
5600
(1500–4588)
7(3–6)
11
(6–36)
Global Mean ± SD 0.782 ± 0.117 164,764 ± 464,692 1990 ± 18 52 ± 254 324 ± 426 398 ± 534
14,911
± 55,757
181 ± 568 27 ± 21
Global Median (Q25-Q75)
0.795
(0.729–0.881)
40,265
(11267–101,558)
1992
(1975–2009)
4 (1–25) 157 (75–350) 246 (150–390)
1500
(300–7500)
21(4–83)
25
(8–47)
*Human Development Index was obtained from United Nations Development Program [31].
†Incidence of IHD was obtained from Global Burden of Disease study [15].
‡National CR capacity calculated using median number of patients program could serve per year (from survey) multiplied by the number of programs in the country (ascertained from
national champions). Value represents the number of patients who could receive CR in a year (i.e., CR spots). For countrywithout a response, national capacity estimated based on regional
median program capacity multiplied by number of programs in that country.
§CR density refers to the number of incident IHD cases per year per CR spot (i.e., national CR capacity).
||Ranking based on density, or ratio of need (i.e., IHD incidence) to supply (i.e., national CR capacity). Lower numbers reflect more CR spots per IHD patient (i.e., of 86 countries where CR
and sufficient information are available such that 1 represents the most spots per IHD patient and 86 is the least spots per patient).
Acronyms: IHD, ischemic heart diseases; CR cardiac rehabilitation; NA, not available; SD, standard deviation; WHO, World Health Organization.
6 K. Turk-Adawi et al. / EClinicalMedicine xxx (xxxx) xxxpatient ratio and case-mix), (vii) core components and other elements
delivered, (viii) dose of CR; (ix) equipment/resources available, and
whether patients are monitored during exercise using telemetry, and
(x) whether the program offers CR in alternative settings (e.g., home-
based, or community-based).2.4. Statistical Analyses
IBM SPSS version 24 was used for analysis [20], and p b .05 consid-
ered statistically significant where exploratory inferential statistics
were performed. Descriptive statistics (e.g., frequency with percentage
or median with quartiles, as appropriate) were used to characterize
CR availability, volumes, capacity, and density, as well as the survey
items related to access and barriers. These were described by country,
WHO region, and/or IHD incidence tertiles [15].
Herein, data from programs nested within countries is presented.
Therefore, clustering of program-level data within countries was taken
into consideration in the inferential tests outlined below.
Differences in the CR availability indicators above (dependent vari-
ables; i.e., programs per country, program volumes, annual capacity,
density) were tested by region and IHD incidence tertile (independent
variables) in an exploratory manner via generalized linear mixed
models (GLMM), to account for clustering of programs, where country
was the random effect. The models were fitted via the Poisson distribu-
tion log link function, because the dependent variables were positively
skewed. Barriers to broader delivery were tested in the same manner,
by WHO region only. Similarly, differences in CR availability (yes/no;
dependent variable) were also tested by region via GLMM, but using a
binomial distribution with logit link function. For each analysis, the dis-
tribution of the residuals was reviewed to consider the model
performance.
Finally, potential drivers of volumes were explored using a two-step
approach: (a) first in a bivariate manner (using t-tests, analysis of vari-
ance or Pearson's correlation as applicable); and where statistically sig-
nificant, (b) using GLMM, where volume was the dependent variable,
and country served as a higher-order variable. A two-step approach
was used because multiple potential factors associated with volume
were considered as this was exploratory, so by running fewer multivar-
iate models this would minimize type 1 error.
Using “country” as a random effect in the drivers of volume model,
the obtained ICCwas= (Random effect)/(Random effect+Residual ef-
fect)ICC = 1.04/(1.04 + 1.00) = 0.51, i.e. 51.1% of variance in this
model is explained by using “country” as random effect. Because vol-
umewas positively skewed, the model was fitted via the Poisson distri-
bution log link function.Please cite this article as: K. Turk-Adawi, M. Supervia, F. Lopez-Jimenez, et
https://doi.org/10.1016/j.eclinm.2019.06.0073. Results
CR was identified to be available in 111/203 countries (54.7%;
Table 1). Data were collected in 93 (83.8% country response rate) coun-
tries (see [19]), from which 1082 (32.1% program response; rate by
country reported elsewhere) surveys were initiated [19]. A random
sub-sample of programs was surveyed in the United States only, and a
non-random convenience sub-sample (due to champion preference)
in Japan, Scotland (1–2 programs per health board/region) and Austria.
3.1. Availability
There were 92 countries in the world that lack any CR (Table 2), of
which 12 (6.1% of the 196 countries with 2016 incidence estimates)
were estimated to have high IHD incidence (Fig. 1) [15].
Availability of any CR in countries by WHO region was: 46/57
(80.7%) countries in Europe, 28/40 (70.0%) countries in Americas, 6/11
(54.5%) countries in SouthEast Asia, 12/22 (54.5%) countries in the East-
ern Mediterranean Region (EMR), 11/26 (42.7%) countries in theWest-
ern Pacific, and 8/47 (17.0%) countries in the African region (p b .001).
The first CR programopened in 1944 inMexico (Table 1). Soon after,
programs opened in Eastern Europe (Germany [1950], Croatia [1957],
and Bulgaria [1958]). More than half of the participating programs (n
= 565; 60.5%), in 30 countries (N = 89; 34.1%), opened since 2000.
There were 5753 CR programs in the world (counting all programs
in the United States).
The median number of programs per country was one; this ranged
from a low of zero in the African and Western Pacific regions, to a
high of four in Europe (shown in countries with CR in Table 1 and
Fig. 2; p b .001). There was a median of zero programs/country in coun-
tries with the lowest IHD incidence, one program in countries with
moderate IHD incidence, and six programs in countrieswith the highest
IHD incidence (p b .001; again, tertiles shown in Fig. 1).
3.2. Volume and Its Drivers
Median program volumes ranged from a low around 20 patients/
program in several countries (e.g., Guatemala, Honduras, Kenya,
Egypt, and Greece), to over 1000 in others (e.g., Scotland, Romania,
Serbia, Argentina, Bulgaria, Nepal; Table 1) per year. They were lowest
in Africa, and highest in Europe (p b .001). Themedian program volume
was 35 patients in countrieswith the lowest IHD incidence, 200 patients
in countries withmoderate IHD incidence, and 250 patients in countries
with the highest IHD incidence (p b .001).
In multivariate models, program volume was statistically signifi-
cantly greater where there were other programs in close proximity,al., Cardiac Rehabilitation Availability and Density around the Globe, ,
Table 2
Estimated annual ischemic heart disease incidence (2016) in countries without cardiac rehabilitation and globally, N = 92.
Country WHO region Human Development Index⁎ IHD incidence† IHD incidence/100,000†
Ukraine Europe 0.743 519,761 1139
Vietnam Western Pacific 0.683 238,156 253
Ethiopia Africa 0.448 138,477 135
Iraq Eastern Mediterranean 0.649 117,130 297
Sudan Eastern Mediterranean 0.490 111,063 282
Myanmar South-East Asia 0.556 108,283 199
Uzbekistan Europe 0.701 90,959 299
Democratic Republic of the Congo Africa 0.592 82,818 104
Yemen Eastern Mediterranean 0.485 69,006 245
Syria Eastern Mediterranean 0.536 57,355 315
North Korea South-East Asia NA 48,117 182
Mozambique Africa 0.418 41,012 142
Ghana Africa 0.579 36,001 127
Madagascar Africa 0.512 32,640 131
Cote d'Ivoire Africa 0.474 31,106 135
Azerbaijan Europe 0.759 28,593 291
Cameroon Africa 0.518 25,761 107
Malawi Africa 0.476 25,374 141
Angola Africa 0.533 24,579 95
Haiti Americas 0.493 23,896 215
Niger Africa 0.353 23,462 117
Cambodia Western Pacific 0.563 22,764 143
Jordan Eastern Mediterranean 0.741 22,639 293
Zimbabwe Africa 0.516 21,766 136
Senegal Africa 0.494 20,843 135
Libya Eastern Mediterranean 0.716 20,254 329
Bolivia Americas 0.674 19,423 175
Burkina Faso Africa 0.402 19,241 103
Zambia Africa 0.579 18,951 114
South Sudan Africa 0.418 17,290 127
Mali Africa 0.442 17,278 96
Guinea Africa 0.414 16,645 129
Chad Africa 0.396 16,436 114
Somalia Eastern Mediterranean NA 15,179 146
Burundi Africa 0.404 13,432 116
Tajikistan Europe 0.627 13,029 152
Oman Eastern Mediterranean 0.796 12,703 270
Rwanda Africa 0.498 11,947 99
Armenia Europe 0.743 11,125 366
Papua New Guinea Western Pacific 0.516 11,091 141
Laos Western Pacific NA 10,390 144
Togo Africa 0.487 9988 135
Albania Europe 0.764 9490 328
Turkmenistan Europe 0.691 9388 171
Sierra Leone Africa 0.420 9247 140
Nicaragua Americas 0.645 7341 119
Central African Republic Africa 0.352 6831 136
Liberia Africa NA 6669 144
Congo Africa 0.592 5921 126
Mauritania Africa 0.513 5612 138
Eritrea Africa 0.420 5386 101
Botswana Africa 0.698 3569 155
Namibia Africa 0.640 3412 136
Lesotho Africa 0.497 2997 140
Guinea-Bissau Africa 0.424 2797 147
Gambia Africa 0.452 2607 127
Gabon Africa 0.6971 2272 129
Swaziland Africa 0.541 1925 144
Guyana Americas 0.638 1814 237
Timor-Leste South-East Asia 0.605 1695 146
Fiji Western Pacific 0.736 1631 189
Suriname Americas 0.725 1468 269
Djibouti Eastern Mediterranean 0.473 1407 145
Bhutan South-East Asia 0.607 1319 165
Equatorial Guinea Africa 0.592 1105 132
Bahamas Americas 0.792 1063 268
Comoros Africa 0.497 1034 133
Cape Verde Africa NA 965 176
Solomon Islands Western Pacific 0.515 753 126
Maldives South-East Asia 0.701 625 172
Belize Americas 0.706 596 159
Saint Lucia Americas 0.735 525 288
Vanuatu Western Pacific 0.597 399 144
Andorra Europe 0.858 336 425
(continued on next page)
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Table 2 (continued)
Country WHO region Human Development Index⁎ IHD incidence† IHD incidence/100,000†
Samoa Western Pacific 0.704 299 151
Saint Vincent and Grenadines Americas 0.722 296 268
Sao Tome and Principe Africa 0.574 263 133
Seychelles Africa 0.782 249 257
Antigua and Barbuda Americas 0.786 235 256
Dominica Americas 0.726 209 282
Tonga Western Pacific 0.721 168 156
Kiribati Western Pacific 0.588 162 143
Federated States of Micronesia Western Pacific 0.638 147 142
Greenland Europe NA 99 200
Marshall Islands Western Pacific NA 98 132
Kosovo Europe NA NA NA
Monaco Europe NA NA NA
Nauru Western Pacific NA NA NA
Palau Western Pacific 0.788 NA NA
Palestine Eastern Mediterranean 0.684 NA NA
Saint Kitts and Nevis Americas 0.765 NA NA
Tuvalu Western Pacific NA NA NA
*Human Development Index was obtained from United Nations Development Program [31].
†Incidence of IHD was obtained from Global Burden of Disease study [15].
Acronyms: FYR, Former Yugoslav Republic; IHD, ischemic heart diseases; NA, not available; WHO, World Health Organization.
8 K. Turk-Adawi et al. / EClinicalMedicine xxx (xxxx) xxxprograms were located in hospitals offering advanced cardiac proce-
dures, therewas systematic referral in the associated hospital, programs
were funded by a combination of private and public sources, programs
offered alternative CRmodels/settings (including residential programs),
therewas a cardiologist on the CR team, and patientswere offered an in-
dividual consult with a physician during the program, programs served
patients at high-risk of cardiovascular disease (primary prevention), the
number of patients served per session and per staff member was larger,
and programs offered smoking cessation services. Volume was statisti-
cally significantly lower where patients had longer wait times, and pro-
grams offered more core components (Table 3).
Globally, there was ≥1 program that offered home-based CR in 38
[40.9%] of the 93 countries that offer CR. There were 152 (12.4%) pro-
grams offering home-based programs, where an estimated 21.4 ±
22.8% of the programs' total patients were served each year (median
of 10.0%; Q1-Q3: 5.0–30.0%). Only 108 (10.0%) programs offeredFig. 1. Global availability of cardiac rehabilitation, by age-standardized ischemic heart disease in
IHD, ischemic heart disease; CR, cardiac rehabilitation.
Please cite this article as: K. Turk-Adawi, M. Supervia, F. Lopez-Jimenez, et
https://doi.org/10.1016/j.eclinm.2019.06.007community-based (in 26/93 [28.0%] countries there was ≥1 program
that offered community-based), where 38.1 ± 32.3% of their patients
were served (median of 27.5%; Q1–Q3: 10.0–61.3%). Eighty-nine
(8.1%) programs offered a hybrid model (i.e., supervised sessions
transitioning to other setting). Eighty-eight (57.9%) programs offering
home-based models reported their program had sufficient home-
based capacity to meet patient demand for that model, while the rest
of the programs (n = 64; 42.1%) reported capacity constraints, such
as insufficient human resources (n = 42, 65.6%) and lack of funding
(n = 31, 48.4%).
3.3. Capacity
Annual program capacitywas lowest in Africa, and highest in Europe
(p b .01; Table 1). The median program capacity was 200 patients in
countries with the lowest IHD incidence, as well as in countries withcidence tertile (2016). Source of incidence estimates: Global Burden of Disease Study [15]
al., Cardiac Rehabilitation Availability and Density around the Globe, ,
Fig. 2. Total number of cardiac rehabilitation programs per country.
9K. Turk-Adawi et al. / EClinicalMedicine xxx (xxxx) xxxmoderate IHD incidence, and 250 patients in countries with the highest
IHD incidence. On average, program volumes were 82.8% of annual
capacity.
Median annual national capacity was lowest in Africa and greatest in
theWestern Pacific followed by Europe (Table 1; p b .001). Median an-
nual national capacity across all countries (i.e., considering zero for
countries without CR) was zero for Africa, and the Western Pacific,
150 for EMR, 200 for South-East Asia, 200 for the Americas, and 2300
for Europe. Median national capacity was zero in countries with the
lowest IHD incidence, zero in countries with moderate IHD incidence,
and 400 in countries with the highest IHD incidence. Global capacity
was 1,655,083 patients/year.
3.4. CR Density
North America, Australia, Japan, and a few countries in Western
Europe had the fewest estimated incident IHD patients/program/year
(197–2089 patients/program; Fig. 3).
CR density in countries with CR ranged from one CR spot per 0.5 in-
cident IHD patient/year (there were three countries with a density less
than one suggesting they could treat other guideline-indicated patients
as well) in Bermuda to per 4480 patients in Nigeria (Table 1; which
should not be over-interpreted as there was only one program in
these two countries) [15]. IHD incidence in countries without CR is
shown in Table 2, reflecting unmet CR need.
Density was poorest in Africa, and best in the Western Pacific (in
countrieswith CR; Table 1; p b .001).Median annual national density in-
cluding countries without CR was zero spots in Africa and the Western
Pacific, one spot per 22 patients in South-East Asia, per 11 in the EMR,
per five in Europe, and per four patients in the Americas.
3.5. Causes
Globally, lack of financial resources was themost strongly rated bar-
rier to greater CR delivery, followed by lack of patient referral, then lack
of human resources (Table 4). Lack of patient referral was rated as a sta-
tistically significantly greater barrier in the Americas and EMR than in
Europe (p b .05 for each); no other differences were observed.Please cite this article as: K. Turk-Adawi, M. Supervia, F. Lopez-Jimenez, et
https://doi.org/10.1016/j.eclinm.2019.06.007Finally, respondents were asked to list any other barriers, and these
included: lack of transport, parking and distance for patients (n = 95,
30.8%), lack of reimbursement/coverage (n= 47, 15.3%), lack of patient
knowledge or awareness (n= 36, 11.7%), patient return-to-work (n=
28, 9.1%), lack physician and healthcare administrator awareness (n =
26, 8.4%), perceived lack of patient motivation (n = 3.9%), lack of pro-
gram capacity (n=9, 2.9%), and lack of trained personnel (n=7, 2.3%).
4. Discussion
Despite the WHO Global Action Plan 2013–2020 for the prevention
of non-communicable diseases recognizing the important role of CR in
stemming the epidemic of CVD [21], for the first time, it has been
established that CR is available in only half of the countries of the
world. This is disheartening given that CVD is the leading cause of
death globally [1], and participation is associatedwith 20% lower cardio-
vascular mortality [4]. Almost 19 million more CR spots would be
needed to treat all incident IHD patients/year [15], and this does not in-
clude heart failure [22], among other patient groups indicated for CR [5].
Clearly, millions of patient deaths could be prevented around theworld
if CR programs were implemented [23,24], with disproportionately
more benefit to be gained in some regions than others. Notably, the
Africa region, where CVD mortality is expected to increase more than
any otherWHO region in the next decade had the lowest CR availability
[25], capacity and density (with 1,345,695 more spots needed to treat
all incident IHD cases annually). In the countries with CR, one-third
has only one program, and another half has ≤5 programs.
Where there is the most pressing need (i.e., high IHD incidence and
low resources, hence high mortality rates and lack of access to cardiac
care), CR is often non-existent. For example, Ukraine, with the highest
estimated IHD incidence of 519,761 [15], does not have any CR. Simi-
larly, Vietnam and Ethiopia do not have CR, despite having 238,156
and 138,477 incident IHD cases annually, respectively [15].
Bangladesh, with its estimated 409,210 incident IHD cases has only
one program; the same situation exists in Nigeria, with its estimated
223,994 incident IHD cases.
The number of patients served per program was shown for the first
time (only previously reported in South Americawhere, consistentwithal., Cardiac Rehabilitation Availability and Density around the Globe, ,
Table 3
Drivers of annual cardiac rehabilitation program volume.
Factor n (%)/mean ±
SD
Annual program volume
(mean ± SD)
Univariate test
Statistic
Univariate
p
GLMM
OR°
95% CI
CR Location F = 0.45 0.636
Urban 774 (71.6%) 503.9 ± 928.0 – –
Suburban 155 (14.3%) 509.9 ± 814.5 – –
Rural 134 (12.4%) 410.7 ± 550.5 – –
Other CR program within 20 km t = 2.57 0.010
Yes 495 (45.7%) 574.7 ± 1104.5 1.20 1.19–1.21
No 516 (47.7%) 420.7 ± 629.0 –
Located in referral center/tertiary facility/academic hospital t = 1.40 0.162
Yes 484 (44.7%) 549.3 ± 1001.1 – – –
No 566 (52.3%) 460.1 ± 809.4
Located in hospital offering coronary bypass surgery t = 2.68 0.008
Yes 441 (40.8%) 601.9 ± 1138.5 1.25 1.24–1.26
No 612 (56.6%) 422.7 ± 647.6 –
Systematic referral in associated hospital t = 2.92 0.017 1.36 1.35–1.38
Yes 647 (59.8%) 586.7 ± 856.1 –
No 182 (16.8%) 439.3 ± 1088.1
CR funding source* F = 12.30 b0.001
Hybrid 268 (24.8%) 695.8 ± 1276.1 –
Public 592 (54.7%) 455.0 ± 619.8 0.83 0.82–0.84
Private 202 (18.7%) 344.4 ± 840.7 0.92 0.91–0.93
Any patient funding
Yes 396 (36.6%) 535.9 ± 1188.5 t = 0.87 0.387 – –
No 668 (61.7%) 472.4 ± 631.4
Estimated program cost to treat one patient (PPP 2016 USD) $1560.2 ±
1686.3
– r =−0.01 0.817 – –
Program offers alternative CR models/settings t =−2.58 0.010
Yes 285 (26.3%) 584.5 ± 720.7 1.05 1.04–1.06
No 630 (58.2%) 478.6 ± 1017.9 –
Residential program t = 2.16 0.0.038
Yes 24 (2.2%) 1880.3 ± 2364.5 2.41 0.39–15.12
No 1058 (97.8%) 618.3 ± 716.2 –
Total number staff on CR team† 5.0 ± 3.2 – r = 0.03 0.375 – –
Cardiologist on the CR team t = 3.24 0.001
Yes 721 (66.6%) 543.8 ± 1004.5 1.16 1.15–1.18
No 205 (18.9%) 359.5 ± 503.7 –
Individual consult with physician t = 2.18 0.029
Yes 697 (64.4%) 534.5 ± 1017.7 1.33 1.31–1.36
No 298 (22.9%) 408.8 ± 529.9 –
Wait times from inpatient discharge to initiate CR (weeks) 3.5 ± 3.6 – r =− 0.86 0.015 0.91 0.90–0.92
Program serves heart failure, transplant and/or VAD patients
(i.e., higher-risk/case-mix)
t = 1.49 0.129
- -
Yes 793 (73.3%) 521.0 ± 911.3
No 60 (5.5%) 324.4 ± 491.2
Program serves patients at high-risk of cardiovascular disease
(primary prevention)
t = 2.77 0.006
Yes 493 (45.6%) 579.3 ± 1034.7 1.32 1.30–1.33
No 360 (33.3%) 405.4 ± 616.5 –
Number of patients served per session 9.1 ± 5.9 – r = 0.31 b0.001 3.04 2.98–3.11
Number of patients served per 1 staff 4.8 ± 8.0 – r =−0.08 0.044 0.99 0.98–0.99
Supervised dose (hours) ‡ 35.2 ± 50.9 – r = 0.03 0.403 – –
Number of core components offered§ 7.5 ± 1.7 – r =−0.09 0.010 0.93 0.94–0.95
Risk factor management t = 1.48 0.140
Yes 928 (85.8%) 511.1 ± 931.7 – –
No 17 (1.6%) 113.0 ± 144.1
Exercise training t = 0.036 0.971
Yes 898 (83.0%) 502.6 ± 939.7 – –
No 54 (5.0%) 508.2 ± 536.4
Patient Education t = 1.19 0.236
Yes 860 (79.5%) 518.5 ± 946.4 – –
No 28 (2.2%) 267.0 ± 315.6
Psychological counseling/stress management t = 1.89 0.060
Yes 651 (60.2%) 521.9 ± 956.3 – –
No 297 (27.4%) 303.2 ± 417.6
Smoking cessation services t = 1.91 0.023
Yes 692 (64.0%) 540.7 ± 991.8 1.07 1.05–1.08
No 252 (23.3%) 394.0 ± 681.8 –
Women-only classes t =−2.32 0.023
Yes 110 (10.1%) 868.6 ± 1774.6 1.01 1.00–1.03
No 820 (75.8%) 446.4 ± 706.3 –
Total equipment|| 9.3 ± 4.4 – r = 0.05 0.152 – –
Telemetry during exercise t =−0.80 0.421
Yes 397 (36.7%) 508.7 ± 982.6 – –
No 513 (47.4%) 510.5 ± 773.3
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Fig. 3. Ischemic heart disease incidence by number of cardiac rehabilitation programs in a country. IHD, ischemic heart disease; CR, cardiac rehabilitation.
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[12], and was surprisingly low. Programs were not quite running at
full capacity, but this is likely explained by insufficient referral. Some
potentially-modifiable factors associatedwith greater program volumes
were offering alternative models (e.g., home-based CR) and having a
mix of private and public program funding sources. We must advocate
for governments to invest in CR and enact policies promoting insurance
company reimbursement, and wemust support CR programs to deliver
services outside major clinical centers so we can reach the vast number
of patients in need. Some guidance on CR delivery in alternative settings
in low-resource countries is available [26,27]. Indeed in the Americas
and Europe where availability and capacity are greatest, there was
more often hybrid funding and more programs offered alternative
models (data not shown).
The fact that programs servedmore patientswhere therewere other
programs in close proximity, when they were situated in an institution
offering advanced cardiac procedures and with systematic inpatient re-
ferral, with a cardiologist on staff and where they served more patients
per session and per staffmember likely reflects the fact that programs at
major academic centers are generally in urban centers and larger, and
hence have higher volumes. The fact that residential programs, thoseNotes to Table 3:
*Private sources included healthcare insurance or patients; public included government; or a hy
funded program in the volume of patients served, but there was between hybrid and private w
†i.e. cardiologist, physiatrist, sports medicine physician, nurse/practitioner, physiotherapist, exe
community health worker, administrative assistant/secretary, other; part-time staff were coun
‡Sessions/week × # weeks in program × # minutes per session.
§Of ten; i.e., initial assessment, risk stratification, supervised exercise, patient education, risk fact
of medication, and communication with a primary healthcare provider.
||e.g., treadmills, cycle ergometers, supplies for cardiovascular risk assessment.
–Not applicable.
°Note that odds ratios can be misleading, and therefore the practical importance of the value s
Acronyms: CR, cardiac rehabilitation; SD, standard deviation; GLMM, generalized linear mixed
States dollar; PPP, purchase power parity.
Abbreviations: km, kilometers; Ref, reference.
Note: Due to missing data, percentages are computed where the denominator is the number o
Please cite this article as: K. Turk-Adawi, M. Supervia, F. Lopez-Jimenez, et
https://doi.org/10.1016/j.eclinm.2019.06.007serving high-risk primary prevention patients, and those where pa-
tients received an individual consultwith a physician again is somewhat
expected, but it is not recommended that programs pursue these ave-
nues to increase reach, as they may be cost-prohibitive. It was discon-
certing to find that programs offering more core components served
fewer patients, as we do want to ensure reach to all patients in need,
while maintaining quality and minimum standards (although higher-
volume programs were more often providing smoking cessation ser-
vices which is encouraging). Research is needed to understand how
countries with the greatest capacity have achieved their heights, includ-
ing the role of session volume, i.e., number of patients per session;while
maintaining safety, so that it can be replicated elsewhere.
4.1. Policy Implications
There is grossly insufficient CR availability and capacity to meet
global service needs. This problemmust be addressed through initiation
of new CR programs and increasing capacity of existing programs (this
is a key finding of this work as program volumes were surprisingly
low in most instances). This requires financial resources, which was
the most commonly-reported barrier to broader provision of CR in thisbrid source. Therewas no statistically significant difference between privately and publicly
ith more patients for hybrid.
rcise specialist/kinesiologist, psychiatrist/psychologist/social worker, dietitian, pharmacist,
ted as 0.5.
ormanagement, nutrition counseling, stressmanagement, smoking cessation, prescription
hould not be over-interpreted.
model; OR, odds ratio; CI, confidence interval; VAD, ventricular assist device; USD, United
f valid responses from responding programs.
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Table 4
Barriers to Broader Cardiac Rehabilitation Delivery, by Country with Cardiac Rehabilitation & WHO Regions [32], N = 111.
Mean ± standard deviation* number of CR programs Lack of patient referral Lack of equipment Lack of space Lack of human resources Lack of financial resources
Africa
Algeria 1 – – – – –
Kenya 3 5.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 4.0 ± 0.0 2.0 ± 0.0
Mauritius 1 5.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Nigeria 1 5.0 ± 0.00 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
South Africa 23 4.4 ± 1.0 1.8 ± 0.9 1.8 ± 1.1 2.0 ± 1.3 3.5 ± 1.7
Regional Mean 5.8 4.5 ± 0.9 2.1 ± 1.3 2.2 ± 1.5 2.4 ± 1.5 3.5 ± 1.6
Americas
Argentina 23 5.0 ± 0.0 3.0 ± 1.7 1.7 ± 1.2 3.3 ± 1.2 3.7 ± 0.6
Barbados 1 5.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 5.0 ± 0.0 4.0 ± 0.0
Bermuda 1 2.0 ± 0.00 2.0 ± 0.0 3.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
Brazil 75 4.2 ± 1.2 2.4 ± 1.5 2.5 ± 1.6 2.9 ± 1.7 3.4 ± 1.5
Canada 170 2.5 ± 1.5 2.7 ± 1.3 3.2 ± 1.4 3.8 ± 1.4 4.3 ± 1.2
Chile 10 5.0 ± 0.0 4.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0
Colombia 50 3.9 ± 1.5 2.1 ± 1.3 2.4 ± 1.3 2.3 ± 1.4 2.9 ± 1.4
Costa Rica 6 3.5 ± 1.6 2.3 ± 2.1 2.5 ± 2.0 3.0 ± 1.7 3.0 ± 1.7
Cuba 8 2.0 ± 1.3 3.4 ± 1.5 3.5 ± 1.9 2.3 ± 1.5 2.4 ± 1.5
Curacao 2 4.0 ± 0.0 2.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0
Dominican Republic 2 5.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 4.0 ± 0.0 2.0 ± 0.0
Ecuador 5 5.0 ± 0.0 1.5 ± 0.7 1.0 ± 0.0 1.5 ± 0.7 1.5 ± 0.7
Guatemala 2 5.0 ± 0.0 3.0 ± 1.4 3.0 ± 1.4 3.5 ± 2.1 2.5 ± 0.7
Honduras 2 3.0 ± 0.0 2.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0 5.0 ± 0.0
Jamaica 3 5.0 ± 0.0 2.0 ± 0.0 1.0 ± 0.0 2.0 ± 0.0 1.0 ± 0.0
Mexico 24 4.9 ± 0.3 1.9 ± 1.5 3.1 ± 1.5 3.1 ± 1.5 3.9 ± 1.4
Panama 1 5.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Paraguay 3 5.0 ± 0.0 2.0 ± 0.0 3.3 ± 1.2 4.0 ± 0.0 3.7 ± 1.5
Peru 10 3.4 ± 1.5 3.7 ± 1.5 3.3 ± 1.8 4.0 ± 1.5 4.1 ± 1.2
United States of America 2632 3.5 ± 1.4 2.6 ± 1.4 3.0 ± 1.4 2.9 ± 1.2 3.2 ± 1.5
Uruguay 12 4.3 ± 1.5 1.5 ± 0.6 1.6 ± 0.9 1.3 ± 0.5 4.5 ± 0.6
Venezuela 9 3.8 ± 1.8 3.6 ± 1.8 1.9 ± 1.5 3.1 ± 1.5 4.4 ± 1.1
Regional Mean 138.7 3.5 ± 1.5 2.5 ± 1.5 2.8 ± 1.5 3.1 ± 1.5 3.5 ± 1.5
Eastern Mediterranean
Afghanistan 1 4.0 ± 0.0 5.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
Bahrain 1 5.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 5.0 ± 0.0 3.0 ± 0.0
Egypt 2 5.0 ± 0.0 4.0 ± 0.0 3.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0
Iran 34 4.8 ± 0.5 2.3 ± 1.3 2.5 ± 1.4 2.8 ± 1.5 4.0 ± 1.2
Lebanon 1 4.0 ± 0.0 1.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 5.0 ± 0.0
Morocco 1 – – – – –
Pakistan 4 5.0 ± 0.0 2.5 ± 2.1 3.0 ± 1.4 3.5 ± 0.7 4.5 ± 0.7
Qatar 1 1.0 ± 0.0 3.0 ± 0.0 5.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Tunisia 1 5.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 2.0 ± 0.0
Regional Mean 5.1 4.6 ± 0.9 2.4 ± 1.4 2.6 ± 1.4 3.1 ± 1.4 4.1 ± 1.1
Europe
Austria 26 2.4 ± 1.9 1.3 ± 0.5 1.3 ± 0.5 2.0 ± 1.4 1.8 ± 1.5
Belarus 5 3.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0
Belgium 48 4.0 ± 1.1 2.1 ± 1.4 2.1 ± 1.1 2.4 ± 1.4 2.9 ± 1.5
Bosnia and Herzegovina 1 1.0 ± 0.0 4.0 ± 0.0 1.0 ± 0.0 4.0 ± 0.0 1.0 ± 0.0
Bulgaria 1 2.0 ± 0.0 2.0 ± 0.0 1.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0
Croatia 3 3.7 ± 0.6 2.7 ± 1.5 2.7 ± 1.5 3.0 ± 1.0 3.7 ± 1.5
Czech Republic 15 3.8 ± 1.3 2.4 ± 1.5 3.0 ± 1.9 3.4 ± 1.3 2.6 ± 1.3
Denmark 35 3.6 ± 0.5 2.2 ± 1.2 2.7 ± 1.1 3.4 ± 1.5 3.4 ± 1.8
England 266 2.0 ± 1.3 2.1 ± 1.1 2.9 ± 1.4 3.3 ± 1.3 3.3 ± 1.3
Estonia 2 2.0 ± 1.4 4.0 ± 1.4 5.0 ± 0.0 5.0 ± 0.0 3.0 ± 0.0
Finland 25 3.8 ± 1.2 1.4 ± 0.7 2.2 ± 1.5 2.8 ± 1.3 2.9 ± 1.3
France 130 3.6 ± 1.6 2.4 ± 1.5 3.3 ± 1.6 3.5 ± 1.5 2.8 ± 1.1
Georgia 17 2.9 ± 1.3 1.1 ± 0.4 2.1 ± 1.6 2.1 ± 1.0 4.0 ± 1.4
Germany 120 4.0 ± 1.3 1.6 ± 0.9 2.2 ± 1.4 2.4 ± 1.3 2.9 ± 1.6
Greece 4 4.3 ± 1.5 1.0 ± 0.0 1.3 ± 0.5 1.8 ± 1.5 4.8 ± 0.5
Hungary 33 4.2 ± 1.3 2.8 ± 1.3 2.6 ± 1.2 3.1 ± 1.4 3.3 ± 1.4
Iceland 4 1.5 ± 0.6 2.0 ± 1.4 1.3 ± 0.5 1.8 ± 1.0 4.5 ± 0.6
Ireland 37 2.6 ± 1.1 1.8 ± 0.8 3.4 ± 1.8 3.8 ± 0.8 3.0 ± 0.7
Israel 22 2.8 ± 1.8 1.4 ± 0.6 2.4 ± 1.7 3.0 ± 1.9 2.8 ± 1.6
Italy 221 3.5 ± 1.5 2.6 ± 1.4 2.7 ± 1.4 3.3 ± 1.5 3.6 ± 1.3
Kazakhstan 1 0 3.0 ± 0.0 2.0 ± 0.0 3.0 ± 0.0 4.0 ± 0.0
Latvia 2 5.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 3.0 ± 0.0 5.0 ± 0.0
Lithuania 25 2.6 ± 1.0 2.4 ± 1.1 2.3 ± 1.1 2.9 ± 1.2 4.6 ± 0.7
Republic of Northern Macedonia 1 4.0 ± 0.0 3.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 5.0 ± 0.0
Malta 1 5.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.00 5.0 ± 0.00 5.0 ± 0.0
Moldova 1 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Netherlands 90 2.1 ± 1.4 1.6 ± 1.2 2.1 ± 1.5 2.4 ± 1.3 2.7 ± 1.6
Northern Ireland 13 2.1 ± 1.5 2.3 ± 1.5 3.2 ± 1.6 4.6 ± 1.0 4.7 ± 0.9
Poland 56 3.0 ± 1.4 2.0 ± 1.3 2.9 ± 1.4 2.7 ± 1.3 3.6 ± 1.4
Portugal 23 4.2 ± 1.3 3.1 ± 1.4 3.5 ± 1.4 3.6 ± 1.5 4.6 ± 0.9
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Table 4 (continued)
Mean ± standard deviation* number of CR programs Lack of patient referral Lack of equipment Lack of space Lack of human resources Lack of financial resources
Romania 3 4.5 ± 0.7 1.5 ± 0.7 1.5 ± 0.7 2.5 ± 2.1 3.0 ± 2.8
Russia 3 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Scotland 69 1.9 ± 1.4 1.6 ± 0.8 2.1 ± 1.1 2.8 ± 1.3 2.6 ± 1.3
Serbia 2 3.0 ± 0.0 2.0 ± 1.4 2.5 ± 0.7 2.5 ± 0.7 3.5 ± 2.1
Slovak Republic 7 3.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 5.0 ± 0.0
Slovenia 2 4.5 ± 0.7 2.0 ± 1.4 2.5 ± 2.1 3.0 ± 1.4 3.5 ± 0.7
Spain 87 3.2 ± 1.4 3.1 ± 1.4 3.2 ± 1.4 3.7 ± 1.4 3.7 ± 1.4
Sweden 69 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0
Switzerland 51 2.8 ± 1.5 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.3 ± 0.5
Turkey 10 4.5 ± 1.4 2.4 ± 1.5 2.4 ± 1.1 3.5 ± 1.2 2.4 ± 1.3
Wales 17 2.2 ± 1.4 2.3 ± 1.2 3.6 ± 1.6 4.7 ± 0.6 4.6 ± 0.6
Regional Mean 37.8 3.1 ± 1.5 2.3 ± 1.3 2.7 ± 1.4 3.2 ± 1.4 3.4 ± 1.4
South-East Asia
Bangladesh 1 5.0 ± 0.0 2.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
India 23 3.9 ± 1.4 2.3 ± 1.4 2.3 ± 1.4 2.4 ± 1.6 3.2 ± 1.8
Indonesia 13 3.5 ± 1.7 2.9 ± 1.5 2.9 ± 1.7 2.8 ± 1.6 3.0 ± 1.4
Nepal 1 4.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0
Sri Lanka 4 1.5 ± 0.7 3.5 ± 2.1 3.0 ± 1.4 3.5 ± 2.1 1.5 ± 0.7
Regional Mean 8.4 3.7 ± 1.5 2.6 ± 1.4 2.7 ± 1.4 2.7 ± 1.6 3.1 ± 1.6
Western Pacific
Australia 314 3.4 ± 1.4 2.5 ± 1.3 3.1 ± 1.4 3.5 ± 1.5 3.5 ± 1.4
Brunei 2 4.5 ± 0.7 2.5 ± 2.1 3.0 ± 2.8 3.0 ± 2.8 2.0 ± 1.4
China 216 3.1 ± 1.4 2.7 ± 1.4 3.1 ± 1.5 3.3 ± 1.3 3.9 ± 1.4
Japan 325 3.0 ± 1.3 2.7 ± 1.6 3.4 ± 1.4 4.3 ± 0.9 3.1 ± 1.1
Malaysia 6 3.7 ± 1.5 2.7 ± 2.1 3.0 ± 1.7 3.0 ± 1.7 3.3 ± 1.5
Mongolia 1 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0 5.0 ± 0.0 5.0 ± 0.0
New Zealand 43 2.9 ± 1.4 2.9 ± 1.4 3.0 ± 1.6 3.4 ± 1.2 3.8 ± 1.3
Philippines 10 4.3 ± 0.5 3.0 ± 1.2 3.6 ± 1.7 3.2 ± 1.1 3.8 ± 1.3
Singapore 7 4.4 ± 0.5 2.0 ± 1.4 2.6 ± 1.7 4.1 ± 1.1 3.4 ± 1.1
South Korea 17 3.1 ± 1.3 1.4 ± 0.5 1.8 ± 1.1 2.1 ± 0.9 3.8 ± 1.3
Taiwan 35 3.1 ± 1.4 2.6 ± 1.5 2.9 ± 1.3 3.2 ± 1.4 2.4 ± 1.3
Regional Mean 88.7 3.3 ± 1.4 2.6 ± 1.4 3.0 ± 1.5 3.4 ± 1.4 3.6 ± 1.4
Global Mean 61.2 3.3 ± 1.5 2.4 ± 1.4 2.8 ± 1.5 3.2 ± 1.4 3.5 ± 1.4
*Scores range from 1 (this is definitely not an issue) to 5 (this is a major issue).
Acronyms: WHO, World Health Organization; FYR, Former Yugoslav Republic.
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be implemented given the need in low and middle-income countries
[27,29]. Offering alternative models such as home-based and
community-based programs could increase capacity of existing CR pro-
grams. Information and communications technology should be
exploited to increase the number of patients each program can treat,
while maintaining program quality and safety [30]. It is essential for
CR associations and other international societies to advocate for CR im-
plementation and reimbursement; advocacy tools are available from
the ICCPR [28]. This association also offers a certification program for
healthcare professionals, which could address the reported barrier of
lack of human resources to deliver CR [31].
4.2. Limitations
There are someweaknesses of studymethodology, primarily related
to generalizability and measurement. First, some programs may not
have been identified, especially in countries where no society or cham-
pion was identified. Therefore, availability, capacity and density could
be under-estimated. Second, though a high response rate at the
country-level of 85% was achieved, response rates among programs
within countries were only 1/3, and hence there may be bias
(i.e., ascertainment bias). In particular, high-resourced programs,
which serve a larger number of patients, may have been more likely
to be represented in the sample; this could result in over-estimates on
capacity indicators.
The other main limitation relates to measurement. First, IHD inci-
dence is estimated by GBD in many countries, and thus measurement
error is expected. Second, volume drivers were chosen based on inves-
tigator opinion from the variables available in the survey; the survey
was developed to assess the nature of programs, not drivers of volume.
There are likely unmeasured factors at play. For this reason, readersPlease cite this article as: K. Turk-Adawi, M. Supervia, F. Lopez-Jimenez, et
https://doi.org/10.1016/j.eclinm.2019.06.007should use caution when interpreting the results from the test of
drivers. These should be considered exploratory at this stage, with fu-
ture research needed to further investigate. Third, national capacity
was computed by multiplying the median capacity in responding pro-
grams by the total number of programs; given not all programs
responded to the survey where capacity was reported, and that
program-reported capacity values were not validated in a random sub-
sample of programs (nor were volumes or drivers of volume assessed);
this would also introduce some error. These values were used to com-
pute density estimates, which therefore should also be interpreted
with some caution.
On a related note, there are somemeasurement issues related to CR
density specifically. It has been estimated based on IHD incidence only
for reasons outlined above, and thereforewithout consideringheart fail-
ure, density is surely over-estimated. Additionally, the term CR density
has been variably operationalized in the literature (e.g., ratio of popula-
tion to number of programs), and hence comparisons to values reported
in other studies should not be undertaken. This is the first study to have
been able to characterize CR density as spots per indicated patient spe-
cifically, and it is hoped that in future studies this more accurate ap-
proach will be applied. Understanding the incidence of CR-indicated
conditions (i.e., IHD and heart failure) on a national basis globally is an-
other important area for further work (crudely, the annual incidence of
CVD globally is 422.7 million cases [2]; given the number of CR spots
globally, this suggests a density of 1 spot per 255 CVD patients), as is
identifying drivers of density.
There also some broader limitations that should be considered. The
first concerns practical importance of the findings. The significance of
the inferential tests reported herein should not be interpreted to sug-
gest significance from a health system, practice or clinical perspective.
Second, due to the nature of the design, causal conclusions should not
be drawn. Finally, due to multiple tests, there could be inflated error.al., Cardiac Rehabilitation Availability and Density around the Globe, ,
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should access CR, it is only available in half of countries around the
world, and where available, density was grossly insufficient to serve
all patients in need. Programs offering alternative models and that are
funded by multiple sources treated more patients than those that are
not. Advocacy for more programs that each serve the maximal number
of patients safely is needed to ensure all guideline-indicated patients
achieve the reductions in cardiovascular mortality and morbidity asso-
ciated with CR participation.
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